Clinical trial Recruiting at 34 sites Phase 3 Interventional Ages 2 to 17

Evaluating Tasimelteon for Pediatric Insomnia

Official title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

Run by Vanda Pharmaceuticals · NCT06953869 · Data updated 2026-11-12

This study is testing if a new sleep medication called tasimelteon can help children and teenagers aged 2 to 17 with insomnia sleep better compared to a placebo.

Quick facts

PhasePhase 3
Study typeInterventional
Ages2 Years to 17 Years
SexAll
Enrollment420 (estimated)
SponsorVanda Pharmaceuticals
Industry-sponsored
Locations35 sites (Dothan, Alabama and 34 other locations)
StatusRecruiting
StartedApril 21, 2025
Main results expectedNovember 2027
Study endsJanuary 2028
Registry record updatedJune 5, 2026
Trial IDNCT06953869 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are males and females aged 2 to 17 years with a confirmed diagnosis of insomnia disorder.

Probably not a fit

Patients with impaired liver function, those who are pregnant or lactating, or those with a history of intolerance to tasimelteon may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, double-blind, randomized study aims to assess the efficacy and safety of a daily oral dose of tasimelteon compared to a placebo in treating insomnia disorder in pediatric patients. Participants aged 2 to 17 years will be enrolled, and the study will monitor their response to the treatment over a specified period. The study is designed to ensure that the sleep disturbances are not caused by other medications, focusing solely on the effects of tasimelteon.

Why it matters

Potential benefit: If successful, this treatment could significantly improve sleep quality and overall well-being in children suffering from insomnia.

How similar studies have gone: Previous studies have shown promise in using melatonin receptor agonists for sleep disorders, suggesting potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Ability and acceptance to provide written informed consent of the participant or legal guardian (and assent as required).
* Confirmed clinical diagnosis of insomnia disorder
* Males and Females between 2 and 17 years, inclusive.
* The sleep disturbance must not be a result of another medication.

Exclusion Criteria:

* Inability to dose daily with tasimelteon or previous intolerance to tasimelteon.
* Indication of impaired liver function.
* Pregnant or lactating females.
* A positive test for drugs of abuse.

Where it's running

  • Vanda Investigational Site
    Dothan, Alabama, United States
    Recruiting
  • Vanda Investigational Site
    Phoenix, Arizona, United States
    Recruiting
  • Vanda Investigational Site
    Irvine, California, United States
    Recruiting
  • Vanda Investigational Site
    Miami, Florida, United States
    Recruiting
  • Vanda Investigational Site
    Miami Lakes, Florida, United States
    Recruiting
  • Vanda Investigational Site
    Winter Park, Florida, United States
    Recruiting
Show 29 more locations
  • Vanda Investigational Site
    Snellville, Georgia, United States
    Recruiting
  • Vanda Investigational Site
    Stockbridge, Georgia, United States
    Recruiting
  • Vanda Investigational Site
    Naperville, Illinois, United States
    Recruiting
  • Vanda Investigational Site
    Worcester, Massachusetts, United States
    Recruiting
  • Vanda Investigational Site
    Great Falls, Montana, United States
    Recruiting
  • Vanda Investigational Site
    Las Vegas, Nevada, United States
    Recruiting
  • Vanda Investigational Site
    Cleveland, Ohio, United States
    Recruiting
  • Vanda Investigational Site
    Columbia, South Carolina, United States
    Recruiting
  • Vanda Investigational Site
    Myrtle Beach, South Carolina, United States
    Recruiting
  • Vanda Investigational Site
    Nashville, Tennessee, United States
    Recruiting
  • Vanda Investigational Site
    Houston, Texas, United States
    Recruiting
  • Vanda Investigational Site
    Plano, Texas, United States
    Recruiting
  • Vanda Investigational Site
    San Antonio, Texas, United States
    Recruiting
  • Vanda Investigational Site
    San Antonio, Texas, United States
    Recruiting
  • Vanda Investigational Site
    Berlin, Germany
    Recruiting
  • Vanda Investigational Site
    Leipzig, Germany
    Recruiting
  • Vanda Investigational Site
    Bydgoszcz, Poland
    Recruiting
  • Vanda Investigational Site
    Gdansk, Poland
    Recruiting
  • Vanda Investigational Site
    Krakow, Poland
    Recruiting
  • Vanda Investigational Site
    Poznan, Poland
    Recruiting
  • Vanda Investigational Site
    Wroclaw, Poland
    Recruiting
  • Vanda Investigational Site
    Great Yarmouth, United Kingdom
    Recruiting
  • Vanda Investigational Site
    Leicester, United Kingdom
    Recruiting
  • Vanda Investigational Site
    Liverpool, United Kingdom
    Recruiting
  • Vanda Investigational Site
    London, United Kingdom
    Recruiting
  • Vanda Investigational Site
    London, United Kingdom
    Recruiting
  • Vanda Investigational Site
    London, United Kingdom
    Recruiting
  • Vanda Investigational Site
    Sheffield, United Kingdom
    Recruiting
  • Vanda Investigational Site
    Lincoln, Nebraska, United States
    Active not recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.